Paratek Pharmaceuticals to Be Acquired in Deal Worth Up to $462 Million
By Colin Kellaher
Paratek Pharmaceuticals on Tuesday said it agreed to be acquired by a pair of healthcare investors in a deal valued at up to $462 million, including the assumption of debt.
Under the agreement, healthcare-investment firm Gurnet Point Capital and investment and holdings company Novo Holdings would pay an initial $2.15 a share in cash for the Boston biopharmaceutical company, a 9.7% premium to Monday's closing price of $1.96.
Paratek said its shareholders would also receive contingent value rights tied to commercial milestone that are potentially worth another 85 cents a share, bringing the total potential deal value to $3 a share, a 53% premium.
The transaction is slated to close in the third quarter.
Novo Holdings is owned by the Novo Nordisk Foundation, a Danish organization that controls healthcare giant Novo Nordisk.
Trading in shares of Paratek was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 06, 2023 09:44 ET (13:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but There’s a Catch
-
Lululemon Earnings: On Track to Meet Expectations Despite Slowdown In Americas
-
What Is Driving Small-Cap Stock Underperformance?
-
After Earnings, Is Zscaler Stock a Buy, a Sell, or Fairly Valued?
-
ASML Fair Value Raised as Outlook Improves